Search Results - "Camez, A."

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial by Nguyen, Quan Dong, Prof Dr, Merrill, Pauline T, MD, Jaffe, Glenn J, Prof, Dick, Andrew D, Prof, Kurup, Shree Kumar, Prof, Sheppard, John, MD, Schlaen, Ariel, MD, Pavesio, Carlos, MD, Cimino, Luca, MD, Van Calster, Joachim, MD, Camez, Anne A, MD, Kwatra, Nisha V, PhD, Song, Alexandra P, MD, Kron, Martina, Prof, Tari, Samir, MD, Brézin, Antoine P, Prof

“…Summary Background Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic…”
Get full text

Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) by Saurat, J.-H., Stingl, G., Dubertret, L., Papp, K., Langley, R.G., Ortonne, J.-P., Unnebrink, K., Kaul, M., Camez, A.

“…Summary Background  Biologic therapies such as adalimumab, a tumour necrosis factor antagonist, are safe and effective in the treatment of moderate to severe…”
Get full text

Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease: Results from CARE by Löfberg, Robert, Louis, Edouard V., Reinisch, Walter, Robinson, Anne M., Kron, Martina, Camez, Anne, Pollack, Paul F.

“…Background: Data regarding the effectiveness of anti‐tumor necrosis factor (TNF) agents for resolution of extraintestinal manifestations (EIMs) are scarce. The…”
Get full text

Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis by Revicki, D., Willian, M.K., Saurat, J.-H., Papp, K.A., Ortonne, J.-P., Sexton, C., Camez, A.

“…Summary Background  Health‐related quality of life (HRQOL) and other patient‐reported outcomes (PROs) are important in evaluating the impact of psoriasis and…”
Get full text

Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients by Vanholder, R, Camez, A, Veys, N, Van Loo, A, Dhondt, A M, Ringoir, S

“…Recently, hirudin was used for the first time as an anticoagulant during hemodialysis in men. Pharmacokinetic data of this compound in end-stage renal failure…”
Get more information

Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis by Vanholder, Raymond C., Camez, Anne A., Veys, Nic M., Soria, Jeannette, Mirshahi, Manouchehr, Soria, Claudine, Ringoir, Séverin

“…Recombinant hirudin: A specific thrombin inhibiting anticoagulant for hemodialysis. The first experience with hirudin as an alternative anticoagulant for…”
Get full text

Mo1296 Quality of Life for Patients With Deep Remission vs. Clinical Remission and Deep Remission vs. Absence of Mucosal Ulceration: 3-Year Data From CHARM/ADHERE by Colombel, Jean-Frederic, Panaccione, Remo, Louis, Edouard, Skup, Martha, Yang, Mei, Pollack, Paul F, Thakkar, Roopal, Camez, Anne A, Chao, Jingdong, Mulani, Parvez, Sandborn, William

Get full text

M1049 Japanese Patients With Moderately to Severely Active Crohn's Disease Experience Improved Quality of Life With Adalimumab Treatment by Hibi, Toshifumi, Watanabe, Mamoru, Camez, Anne A, Alam, Shamsul, Chao, Jingdong, Mulani, Parvez, Yang, Mei

Get full text

A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis by Schiele, F, Vuillemenot, A, Kramarz, P, Kieffer, Y, Soria, J, Soria, C, Camez, A, Mirshahi, M C, Bassand, J P

“…Recombinant hirudin, a pure, specific antithrombin could be more effective than heparin in the treatment of deep vein thrombosis, but its short half-life…”
Get more information

Refludan: Le premier traitement de la thrombopénie induite par l'héparine (TIH) de type II by CAMEZ, A

Get full text

T1239 Adalimumab Treatment Results in Deep Remission for Patients With Moderate to Severe Ileocolonic Crohn's Disease: Results From EXTEND by Colombel, Jean-Frédéric, Rutgeerts, Paul J, Sandborn, William J, Camez, Anne A, Pollack, Paul F, Chen, Naijun, Yang, Mei, Mulani, Parvez, Chao, Jingdong

Get full text

41a Prediction of Long-Term Clinical Remission for Adalimumab-Treated Patients With Crohn's Disease by Identification of Appropriate Dichotomizing Points for SES-CD by Reinisch, Walter, Rutgeerts, Paul J, Panaccione, Remo, D'Haens, Geert R, Thakkar, Roopal, Yu, Andrew P, Li, Zhiyi, Camez, Anne A, Pollack, Paul F, Yang, Mei, Chao, Jingdong, Mulani, Parvez

Get full text

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial by Louis, Edouard, Löfberg, Robert, Reinisch, Walter, Camez, Anne, Yang, Mei, Pollack, Paul F., Chen, Naijun, Chao, Jingdong, Mulani, Parvez M.

“…Crohn's disease negatively affects patients’ quality of life and ability to work. We investigated the impact of adalimumab on work productivity, daily…”
Get full text

Recombinant hirudin (HBW 023): biological data of ten patients with severe venous thrombo-embolism by Bridey, F, Dreyfus, M, Parent, F, Bros, A, Fischer, A M, Camez, A, Simonneau, G, Duroux, P, Meyer, D

“…This study reports on the biological data of ten patients with acute venous thrombo-embolism. They were treated for 5 days with continuous intravenous infusion…”
Get more information

Achievement of early deep remission is associated with lower rates of weekly dosing for adalimumab-treated patients with Crohn's disease by Sandborn, W, Colombel, J, Lomax, K, Pollack, P, Thakkar, R, Camez, A, Chen, N, Yang, M, Chao, J, Mulani, P

Get full text

Adalimumab Therapy reduces the presence of Extraintestinal Manifestations in patients with Crohnʼs Disease: The CARE Trial: P-0118 by Louis, E, Lofberg, R, Reinisch, W, Kron, M, Camez, A, Robinson, A, Pollack, P

Get full text

P212 Clinical outcomes in patients with moderate versus severe Crohn's disease at baseline: Analysis from CARE by Löfberg, R., Louis, E., Reinisch, W., Robinson, A., Kron, M., Camez, A., Pollack, P.

Get full text

The lupus anticoagulant and its role in thrombosis by Tobelem, G, Cariou, R, Camez, A

“…The lupus anticoagulant is usually found in the plasma of patients with systemic lupus erythematosus. Lupus anticoagulants are antibodies to phospholipids and…”
Get more information

Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn's disease by Sandborn, W, Colombel, J, Rutgeerts, P, Yang, M, Lomax, K, Pollack, P, Thakkar, R, Camez, A, Chen, N, Chao, J, Mulani, P

Get full text

Adalimumab is effective for inducing clinical remission at week 4 regardless of baseline corticosteroid use by Colombel, J, Rutgeerts, P, Reinisch, W, Sandborn, W, Panés, J, Camez, A, Pollack, P, Thakkar, R, Huang, B, Yang, M, Chao, J, Mulani, P

Get full text